We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 41-60 of 623 results
  1. EBV-associated lymphoproliferative disease post-CAR-T cell therapy

    Epstein–Barr virus (EBV)-associated lymphoproliferative diseases (EBV-LPDs) are common complications that occur after solid organ transplantation or...

    Shiyuan Zhang, **aoxi Zhou, ... Liang Huang in Frontiers of Medicine
    Article 08 February 2024
  2. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a sco** review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis

    Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome driven by pathologic activation of cytotoxic T-lymphocytes and...

    Johanna Knauft, Thomas Schenk, ... Sebastian Birndt in Leukemia
    Article Open access 18 January 2024
  3. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

    Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies...

    Yong-Pyo Lee, Sang Eun Yoon, ... Won Seog Kim in International Journal of Hematology
    Article 24 July 2021
  4. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma

    Natural killer T cell lymphoma (NKTCL) is highly aggressive, with advanced stage patients poorly responding to intensive chemotherapy. To explore...

    Jie **ong, Shu Cheng, ... Wei-Li Zhao in Signal Transduction and Targeted Therapy
    Article Open access 06 March 2024
  5. The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis

    This study was designed to explore the relative efficacy and toxicity of upfront radiotherapy (RT) and late RT in combination treatments for patients...

    Yue Cui, Yuyi Yao, ... Quanguang Ren in Annals of Hematology
    Article 27 October 2021
  6. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

    Background

    Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical...

    Yuankai Shi, Jianqiu Wu, ... Qian Wang in Journal of Hematology & Oncology
    Article Open access 12 January 2021
  7. Loss of sCD3 in hepatosplenic T cell lymphoma — a- case report

    Hepatosplenic T cell lymphoma is a rare subtype of non-Hodgkin lymphoma affecting younger adult men and immunocompromised individuals. The neoplastic...

    Jian Li, Mustafa Saydoon, ... Sharon Jackson in Journal of Hematopathology
    Article 03 January 2022
  8. The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients

    To investigate the prognostic impact of serum beta-2 microglobulin (B2M) in adult lymphoma-associated hemophagocytic lymphohistiocytosis (HLH). The...

    Ze **, Yi Miao, ... Wenyu Shi in Annals of Hematology
    Article 25 January 2024
  9. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma

    T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an...

    Neetha Parameswaran, Li** Luo, ... Feng Lin in Leukemia
    Article 12 August 2023
  10. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study

    Background . Central nervous system lymphoma (CNSL) is an aggressive lymphoma. Orelabrutinib, an oral Bruton tyrosine kinase inhibitor, is a new...

    **g-**g Wu, Wen-Hua Wang, ... Ming-Zhi Zhang in Investigational New Drugs
    Article 09 February 2022
  11. Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant

    We evaluated the impact on survival of antithymocyte globulin conditioning (TLI-ATG) with radiation (RT) boost to high risk or residual disease...

    M. L. Dworkin, A. L. Jiang, ... R. T. Hoppe in Bone Marrow Transplantation
    Article 20 October 2021
  12. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma

    TP53 mutation ( TP53 mut ) occurs in 10–20% of diffuse large B-cell lymphoma (DLBCL) cases and serves as an unfavorable biomarker of DLBCL progression....

    Ying Fang, Mu-Chen Zhang, ... Wei-Li Zhao in Signal Transduction and Targeted Therapy
    Article Open access 06 October 2023
  13. Extranodal NK/T-cell lymphoma in Tunisia: clinicopathological features, immunophenotype and EBV infection

    Background

    Extranodal NK/T-cell lymphomas (ENKTL) are rare non-Hodgkin’s lymphomas with aggressive clinical behavior. ENKTL are frequently associated...

    Nabiha Missaoui, Sarra Mestiri, ... Sihem Hmissa in Journal of the Egyptian National Cancer Institute
    Article Open access 22 October 2019
  14. A genetic profiling guideline to support diagnosis and clinical management of lymphomas

    The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization...

    Margarita Sánchez-Beato, Miriam Méndez, ... Mariano Provencio in Clinical and Translational Oncology
    Article Open access 06 September 2023
  15. Extranodal NK-T Cell Lymphoma, Nasal Type: Retrospective Analysis of Real-World Data

    Peripheral T cell lymphomas constitute nearly 15% of all cases on non-Hodgkin lymphoma. Of these, NK-T cell lymphoma nasal type is a rare and...

    Sneha J. Bothra, Pragya Bhandari, ... Dinesh Bhurani in Indian Journal of Hematology and Blood Transfusion
    Article 28 September 2019
  16. Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas

    Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with γδ T-cell receptors. The...

    Ibrahim N. Muhsen, Riad El Fakih, ... Mahmoud Aljurf in Clinical Hematology International
    Article Open access 22 June 2022
  17. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature

    Background

    Extranodal natural killer/T-cell lymphoma is a rare, aggressive non-Hodgkin lymphoma that is treated upfront mostly with L -asparaginase...

    Elizabeth McGehee, Hetalkumari Patel, ... Praveen Ramakrishnan Geethakumari in Journal of Medical Case Reports
    Article Open access 30 April 2021
  18. Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma

    Mantle cell lymphoma is a rare and incurable non-Hodgkin lymphoma with a heterogenous clinical presentation. Typically, treatment consists of...

    Radhika Takiar, Tycel Phillips in Current Treatment Options in Oncology
    Article 15 September 2021
  19. Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies

    Silent inactivation of L-asparaginase (L-Asp) represents rapid clearance of L-Asp by anti-L-Asp IgG antibodies without clinical symptoms. Measurement...

    Takayuki Nakamura, Shuki Oya, ... Koji Nagafuji in International Journal of Hematology
    Article 16 February 2024
Did you find what you were looking for? Share feedback.